.png){kind=icon}
.png){kind=icon}
Return
Thyroid Carcinoma, Version 2.2022
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2022.0040.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carci-noma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carci-noma is almost uniformly lethal, and iodine-131 imaging and radioac-tive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carci-noma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hu???rthle cell carcinoma).
Keywords:
TYROSINE KINASE INHIBITORS
PHASE-II TRIAL
EXTERNAL-BEAM RADIATION
HURTHLE CELL-CARCINOMA
TERM-FOLLOW-UP
PROGNOSTIC-FACTORS
ASSOCIATION GUIDELINES
UNITED-STATES
LOW-RISK
SERUM CALCITONIN
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations